TIME Pharmaceuticals : Touching Lives, Delivering Promises
"स्वस्थ नेपाल हाम्रो अभियान; गुणस्तरीय औषधि हाम्रो पहिचान"
TIME Pharmaceuticals: Thrive For Effectiveness
Generic Name
Composition
Therapeutic Category
Division
Tranexamic acid
Tranexamic acid 250mg Capsules
Tranexamic acid 500mg Capsules
Anti-fibrinolytic
COSMO
| BRAND | COMPOSITION | DESCRIPTION |
|---|---|---|
| TRANCAP 250 |
Each capsule contains: Tranexamic Acid BP 250mg |
Size '2' hard gelatin capsule having yellow body and green cap. |
| TRANCAP 500 |
Each capsule contains: Tranexamic Acid BP 500mg |
White compacted powder filled in size '0' hard gelatin capsule with blue cap and grey body |
PATIENT INFORMATION |
|---|
|
Administration: May be taken with or without food Pregnancy :Category B Storage: Store below 25°C; Keep out of reach of children. Missed dose: Take the missed dose as soon as you remember; Skip the missed dose if it is almost time for your next scheduled dose; Do not take extra medicine to make up the missed dose. |
PHARMACOLOGY
Pharmacotherapeutic Group: Anti-fibrinolytic agent
Pharmacodynamic properties:
Anti-fibrinolytic agent: Tranexamic acid is an antifibrinolytic agent that competitively inhibits the activation of plasminogen to plasmin and prevents the degradation of fibrin clot. At much higher concentrations it is a non-competitive inhibitor of plasmin.
In melasma: Melasma is tan or dark skin coloration. It is the hyperpigmentation due to overproduction of melanin. Tranexamic acid interferes with tyrosinase enzyme and inhibits melanin synthesis.
Pharmacokinetic properties:
Absorption: Absorbed from the GI tract; peak plasma concentrations after 3 hr (oral); Bioavailability: 30-50%, unaffected by food intake.
Distribution: Widely throughout the body. Protein-binding: Very low. Crosses the placenta, blood brain barrier and distributed into breast milk.
Excretion: Urine (as unchanged drug); Elimination half-life: 2hr.
INDICATIONS
Dermal, epidermal and mixed melasma; Dermal erythema; Vaginal bleeding; Menorrhagia; Dentistry; Hemophilia; Injuries and trauma; Surgery; Nasal bleeding.
DOSE
As anti-fibrinolytic agent: 500mg two to three times daily.
In melasma: 250mg twice daily for 3 months.
CONTRAINDICATIONS
Severe renal failure, Hypersensitivity, Thromboembolic disease, subarachnoid bleeding, Colour vision disorders, History of convulsion, Disseminated intravascular coagulation; consumption coagulopathy.
SPECIAL PRECAUTIONS
Mild to moderate renal impairment, Irregular menstrual bleeding, Previous history of thromboembolic disease, Haematuria, Oral contraceptives.
ADVERSE DRUG REACTIONS
Diarrhoea, nausea, vomiting, disturbances in colour vision, giddiness, thromboembolic events.
DRUG INTERACTIONS
Potentially Fatal: Increased risk of thrombus formation with estrogens, Factor IX complex concentrates or anti-inhibitor coagulant concentrates. Increased risk of fatal thrombotic complications with tretinoin in acute promyelocyticleukaemia.
PRESENTATION
TRANCAP 250: Each box contains 10 blister packs of 10 capsules per strip
TRANCAP 500: Each box contains 10 blister packs of 10 capsules per strip
